informe tecnológico de patentes
... AB - Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by the expression of mutant huntingtin protein (Htt). Suppression of Htt expression, using RNA interference, might be an effective therapy. However, if reduction of wild-type protein is not well tolerated in t ...
... AB - Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by the expression of mutant huntingtin protein (Htt). Suppression of Htt expression, using RNA interference, might be an effective therapy. However, if reduction of wild-type protein is not well tolerated in t ...
Novel therapies for treatment of gout and hyperuricemia Review Gout Robert Terkeltaub
... substantial fraction of patients on submaximal allopurinol [32]. An approach of this nature, using certain drugs with wider availability than benzbromarone (for example, losartan, and fenofibrate) [33,34] but with less potent uricosuric action than primary uricosurics such as probenecid, has to date ...
... substantial fraction of patients on submaximal allopurinol [32]. An approach of this nature, using certain drugs with wider availability than benzbromarone (for example, losartan, and fenofibrate) [33,34] but with less potent uricosuric action than primary uricosurics such as probenecid, has to date ...
Treatment Challenges of Group A Beta
... penicillin-susceptible Prevotella spp. Amoxicillin-clavulanate is also effective against potentially interfering β-lactamase-producing Gram-negative bacilli (i.e., Prevotella spp.). In contrast, these microorganisms are relatively resistant to the extended spectrum and second- and third-generation c ...
... penicillin-susceptible Prevotella spp. Amoxicillin-clavulanate is also effective against potentially interfering β-lactamase-producing Gram-negative bacilli (i.e., Prevotella spp.). In contrast, these microorganisms are relatively resistant to the extended spectrum and second- and third-generation c ...
Limitations of Trauma-Focused Therapies for Treating
... To understand the efficacy of PE, let’s look at one of the controlled clinical trials in which rates of PTSD remission, partial and complete, are provided. Schnurr, Friedman, Engel, Foa, et al. (2007) compared the efficacy of PE to present‐focused therapy and wait‐list as controls (N = 284). Trea ...
... To understand the efficacy of PE, let’s look at one of the controlled clinical trials in which rates of PTSD remission, partial and complete, are provided. Schnurr, Friedman, Engel, Foa, et al. (2007) compared the efficacy of PE to present‐focused therapy and wait‐list as controls (N = 284). Trea ...
Fanconi Anemia Research Fund
... Fanconi anemia is a complex disease that can affect many systems of the body. Patients are at risk for bone marrow failure, leukemia, and squamous cell carcinoma. They also can be affected by other facets of the disease, such as endocrine, gastrointestinal or radial ray abnormalities. This checklist ...
... Fanconi anemia is a complex disease that can affect many systems of the body. Patients are at risk for bone marrow failure, leukemia, and squamous cell carcinoma. They also can be affected by other facets of the disease, such as endocrine, gastrointestinal or radial ray abnormalities. This checklist ...
Single Nucleotide Polymorphism (SNP) of the Endothelial Nitric
... Review Board of the Polytechnic University of Marche, Umberto I Hospital, Ancona, Italy. All participants provided their written informed consent to take part in this study. The patients (n 5 70) in our study consisted of infertile men who had been referred for an infertility workup at our andrology ...
... Review Board of the Polytechnic University of Marche, Umberto I Hospital, Ancona, Italy. All participants provided their written informed consent to take part in this study. The patients (n 5 70) in our study consisted of infertile men who had been referred for an infertility workup at our andrology ...
Exclusion of known corneal dystrophy genes in an autosomal
... Purpose: With advances in phenotyping tools and availability of molecular characterization, an increasing number of phenotypically and genotypically diverse inherited corneal dystrophies are described. We aimed to determine the underlying causative genetic mechanism in a three-generation pedigree af ...
... Purpose: With advances in phenotyping tools and availability of molecular characterization, an increasing number of phenotypically and genotypically diverse inherited corneal dystrophies are described. We aimed to determine the underlying causative genetic mechanism in a three-generation pedigree af ...
A Control Theoretic Approach to HIV/AIDS Drug Dosage Design and
... some studies [4, 5, 6] have shown that there is a higher mortality rate for patients who start therapy in the advanced stages of the disease as opposed to those who started early. The main reason for the lack of consensus on when best to initiate therapy, as well as other HIV issues, is that the che ...
... some studies [4, 5, 6] have shown that there is a higher mortality rate for patients who start therapy in the advanced stages of the disease as opposed to those who started early. The main reason for the lack of consensus on when best to initiate therapy, as well as other HIV issues, is that the che ...
What is the treatment for myeloma?
... require active treatment. It is very important to establish the correct diagnosis distinguishing MGUS and asymptomatic myeloma from active or symptomatic myeloma, which does require treatment. ...
... require active treatment. It is very important to establish the correct diagnosis distinguishing MGUS and asymptomatic myeloma from active or symptomatic myeloma, which does require treatment. ...
WAO Guideline for the Management of Hereditary Angioedema
... latter were invited to provide additional data on their products. These representatives did not take part in any voting procedures.2 Four of the 5 pharmaceutical companies producing drugs for HAE (CSL Behring, Marburg, Germany; Dyax, Cambridge, MA; Pharming, Leiden, the Netherlands; Shire, Dublin, I ...
... latter were invited to provide additional data on their products. These representatives did not take part in any voting procedures.2 Four of the 5 pharmaceutical companies producing drugs for HAE (CSL Behring, Marburg, Germany; Dyax, Cambridge, MA; Pharming, Leiden, the Netherlands; Shire, Dublin, I ...
Epigenetic Regulation ofbdnfGene Transcription in the
... is in a highly methylated or unmethylated basal state, the two different primer sets will be preferentially sensitive to alterations in methylation (Li and Dahiya, 2002). For example, a specific CpG island that is highly methylated in the basal state is much more likely to reveal demethylation chang ...
... is in a highly methylated or unmethylated basal state, the two different primer sets will be preferentially sensitive to alterations in methylation (Li and Dahiya, 2002). For example, a specific CpG island that is highly methylated in the basal state is much more likely to reveal demethylation chang ...
Development of a repressible mycobacterial
... mutants of M. tuberculosis as well as to characterize them during experimental infection (7–9). Even though these tools proved to be quite useful, they have the disadvantage that Tc functions as an inducer of gene expression and has therefore to be removed to silence the gene under investigation. Fo ...
... mutants of M. tuberculosis as well as to characterize them during experimental infection (7–9). Even though these tools proved to be quite useful, they have the disadvantage that Tc functions as an inducer of gene expression and has therefore to be removed to silence the gene under investigation. Fo ...
Anterior boundaries of Hox gene expression in mesoderm
... posterior ectoderm can be seen with all three probes at this time. At 8 days P.c., closure of the neural tube proceeds from the middle of the embryo towards the anterior and posterior ends. It is evident that Hox gene transcript can be detected in neural ectoderm prior to closure at the posterior en ...
... posterior ectoderm can be seen with all three probes at this time. At 8 days P.c., closure of the neural tube proceeds from the middle of the embryo towards the anterior and posterior ends. It is evident that Hox gene transcript can be detected in neural ectoderm prior to closure at the posterior en ...
Allergic Rhinitis - Department of Family and Community Medicine
... in young children and produce similar symptoms, it is very difficult to diagnose allergic rhinitis in the first 2 or 3 years of life. The prevalence of allergic rhinitis peaks in the second to fourth decades of life and then gradually diminishes.3,4 The frequency of sensitization to inhalant allerge ...
... in young children and produce similar symptoms, it is very difficult to diagnose allergic rhinitis in the first 2 or 3 years of life. The prevalence of allergic rhinitis peaks in the second to fourth decades of life and then gradually diminishes.3,4 The frequency of sensitization to inhalant allerge ...
Familial idiopathic methemoglobinemia revisited: original
... control subjects, with a significance level of 0.05. Allele frequencies were compared between subjects with glaucoma and control subjects, with the 2 test for 2 ⫻ n tables, where n is the number of alleles. Rare alleles were pooled so that all expected cell values were greater than 2. P ⬍ 0.05 was ...
... control subjects, with a significance level of 0.05. Allele frequencies were compared between subjects with glaucoma and control subjects, with the 2 test for 2 ⫻ n tables, where n is the number of alleles. Rare alleles were pooled so that all expected cell values were greater than 2. P ⬍ 0.05 was ...
Urticaria and angioedema R E V I E W Open Access Amin Kanani
... and chronic urticaria [4]. First-generation, sedating antihistamines may be used as adjunctive therapy in those patients who have difficulty sleeping due to nocturnal symptoms [1-3]. Table 2 provides a list of commonly used second- and first-generation antihistamines and their recommended dosing reg ...
... and chronic urticaria [4]. First-generation, sedating antihistamines may be used as adjunctive therapy in those patients who have difficulty sleeping due to nocturnal symptoms [1-3]. Table 2 provides a list of commonly used second- and first-generation antihistamines and their recommended dosing reg ...
Spring 2005 - AT Children`s Project
... the rat, which may possess neurological abnormalities similar to those seen in patients. For years mice have been genetically manipulated in order to gain a better understanding of human disease. For example, researchers have added genes to the mouse’s already existing genetic repertoire, creating s ...
... the rat, which may possess neurological abnormalities similar to those seen in patients. For years mice have been genetically manipulated in order to gain a better understanding of human disease. For example, researchers have added genes to the mouse’s already existing genetic repertoire, creating s ...
Concise Review Multiple Myeloma of the Disease and Treatment Options
... Continued research on the role of high-dose chemotherapy with autologous and allogeneic transplant. The magnitude of benefit and patient population(s) likely to benefit remain uncertain. Transplant performed as part of initial (induction) therapy is shown to produce results similar to transplant don ...
... Continued research on the role of high-dose chemotherapy with autologous and allogeneic transplant. The magnitude of benefit and patient population(s) likely to benefit remain uncertain. Transplant performed as part of initial (induction) therapy is shown to produce results similar to transplant don ...
Christian Jackisch
... trastuzumab in the first-line setting – similar magnitudes of improvement have been reported only rarely (in any therapeutic area) – trastuzumab is the only HER2-targeted therapy shown to improve survival in MBC patients with HER2-positive tumours – benefits of trastuzumab were apparent regardless o ...
... trastuzumab in the first-line setting – similar magnitudes of improvement have been reported only rarely (in any therapeutic area) – trastuzumab is the only HER2-targeted therapy shown to improve survival in MBC patients with HER2-positive tumours – benefits of trastuzumab were apparent regardless o ...
Alu repeat analysis in the complete human genome: trends and
... 30 bp insertion in the right monomer (Jelinek et al., 1980; Ullu and Tschudi, 1984). The 3 end of the Alu element has a long stretch of adenine residues, and is flanked by 4–10 bp of direct repeats at the site of insertion. These elements contain a pol III promoter that has been proposed to be invo ...
... 30 bp insertion in the right monomer (Jelinek et al., 1980; Ullu and Tschudi, 1984). The 3 end of the Alu element has a long stretch of adenine residues, and is flanked by 4–10 bp of direct repeats at the site of insertion. These elements contain a pol III promoter that has been proposed to be invo ...
Lymphedema, Role of truncal clearance as a therapy
... must first be directed at lymphatic territories, such as the trunk, so that they are adequately prepared to receive lymph from subsequently treated lymphedematous regions such as the arm or leg. Treating truncal lymphatics is also needed in the presence of often unrecognized acute truncal edema. Thi ...
... must first be directed at lymphatic territories, such as the trunk, so that they are adequately prepared to receive lymph from subsequently treated lymphedematous regions such as the arm or leg. Treating truncal lymphatics is also needed in the presence of often unrecognized acute truncal edema. Thi ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.